대한약침학회지 (Journal of Pharmacopuncture)

  • 제26권1호
  • /
  • Pages.38-43
  • /
  • 2023
  • /
  • 2093-6966(pISSN)
  • /
  • 2234-6856(eISSN)
대한약침학회 (KOREAN PHARMACOPUNCTURE INSTITUTE)
권호 표지
DOI QR코드

DOI QR Code

Effectiveness of the Shugan Jieyu Capsule against Psychiatric Symptoms in Epilepsy: a protocol for systematic review and meta-analysis

  • Sejin, Kim (College of Korean Medicine, Kyung Hee University) ;
  • Yunna, Kim (College of Korean Medicine, Kyung Hee University) ;
  • Seung-Hun, Cho (College of Korean Medicine, Kyung Hee University)
  • 투고 : 2022.08.02
  • 심사 : 2023.02.22
  • 발행 : 2023.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: Psychiatric symptoms in epilepsy are very common, and the most common symptoms are depression, insomnia, and anxiety. These symptoms not only lower the quality of life of epilepsy patients, but also elevate the risk of epileptic seizures. There are no specific criteria for the available antiepileptic drugs to ameliorate these symptoms in patients with epilepsy, and there is a lack of evidence to support the efficacy and safety of existing drugs. The Shugan Jieyu capsule (SJC) is a traditional herbal medicine composed of Acanthopanax senticosus and Hypericum perforatum and is reported to be effective in relieving psychiatric symptoms. The purpose of this study was to assess the efficacy of SJC as a treatment for psychiatric symptoms in epilepsy patients. Methods: Electronic databases will be investigated for publications in English, Korean, Japanese, and Chinese. The participants of the study are epilepsy patients with psychiatric symptoms diagnosed using any validated criteria. All types of controls will be compared-placebo, conventional treatments, and no treatment-to groups treated with SJC or modified SJC. We will measure the degree of improvement in psychiatric symptoms and check epileptic symptoms, such as the frequency of seizures. The study selection and data extraction will be performed by two independent reviewers, who will also assess methodological quality using the risk-of-bias tool by Cochrane. We will use Review Manager software (RevMan) to carry out all statistical analyses. Results: This systematic review and meta-analysis will be performed in accordance with the PRISMA-P statement. Conclusion: This systematic review is the first study to assess the efficacy and safety of SJC for the treatment of psychiatric symptoms in epilepsy. We expect that this study will provide clinically applicable evidence for patients with epilepsy when selecting drug treatments.

키워드

과제정보

Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1F1A1067569) supported this work. Thank you for the Undergraduate Research Program (URP) grant of Kyung Hee University College of Korean Medicine, Republic of Korea.

참고문헌

  1. Michaelis R, Tang V, Nevitt SJ, Wagner JL, Modi AC, LaFrance WC Jr, et al. Psychological treatments for people with epilepsy. Cochrane Database Syst Rev. 2020;8(8):CD012081.
  2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-9. https://doi.org/10.1056/NEJM200002033420503
  3. Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, Maxwell CJ, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology. 2013;80(6):590-9. https://doi.org/10.1212/WNL.0b013e31827b1ae0
  4. Kennedy SH. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci. 2008;10(3):271-7. https://doi.org/10.31887/DCNS.2008.10.3/shkennedy
  5. Kanner AM. Depression and epilepsy: a bidirectional relation? Epilepsia. 2011;52 Suppl 1:21-7. https://doi.org/10.1111/j.1528-1167.2010.02907.x
  6. Danzer SC. Depression, stress, epilepsy and adult neurogenesis. Exp Neurol. 2012;233(1):22-32. https://doi.org/10.1016/j.expneurol.2011.05.023
  7. Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72(2):184-91. https://doi.org/10.1002/ana.23601
  8. Quigg M, Gharai S, Ruland J, Schroeder C, Hodges M, Ingersoll KS, et al. Insomnia in epilepsy is associated with continuing seizures and worse quality of life. Epilepsy Res. 2016;122:91-6. https://doi.org/10.1016/j.eplepsyres.2016.02.014
  9. Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48(12):2336-44. https://doi.org/10.1111/j.1528-1167.2007.01222.x
  10. Macedo PJOM, Oliveira PS, Foldvary-Schaefer N, Gomes MDM. Insomnia in people with epilepsy: a review of insomnia prevalence, risk factors and associations with epilepsy-related factors. Epilepsy Res. 2017;135:158-67. https://doi.org/10.1016/j.eplepsyres.2017.05.014
  11. Stephen LJ, Wishart A, Brodie MJ. Psychiatric side effects and antiepileptic drugs: observations from prospective audits. Epilepsy Behav. 2017;71(Pt A):73-8. https://doi.org/10.1016/j.yebeh.2017.04.003
  12. Zhang LL, Zeng LN, Li YP. Side effects of phenobarbital in epilepsy: a systematic review. Epileptic Disord. 2011;13(4):349-65. https://doi.org/10.1684/epd.2011.0444
  13. Foldvary N, Perry M, Lee J, Dinner D, Morris HH. The effects of lamotrigine on sleep in patients with epilepsy. Epilepsia. 2001;42(12):1569-73. https://doi.org/10.1046/j.1528-1157.2001.46100.x
  14. Trivedi MH, Kurian BT. Managing depressive disorders in patients with epilepsy. Psychiatry (Edgmont). 2007;4(1):26-34.
  15. Maguire MJ, Weston J, Singh J, Marson AG. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev. 2014;2014(12):CD010682.
  16. Guo Y, Ding XY, Lu RY, Shen CH, Ding Y, Wang S, et al. Depression and anxiety are associated with reduced antiepileptic drug adherence in Chinese patients. Epilepsy Behav. 2015;50:91-5. https://doi.org/10.1016/j.yebeh.2015.06.042
  17. Curran S, de Pauw K. Selecting an antidepressant for use in a patient with epilepsy. Safety considerations. Drug Saf. 1998;18(2):125-33. https://doi.org/10.2165/00002018-199818020-00004
  18. Gilliam FG, Black KJ, Carter J, Freedland KE, Sheline YI, Tsai WY, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Ann Neurol. 2019;86(4):552-60. https://doi.org/10.1002/ana.25561
  19. Wani M, Polshettiwar SA, Parakh SR, Chopade VV. Herbal medicine and its standardization. Pharm Rev. 2007;5(6):1-2.
  20. Sun X, Chen A, Xu X, Zhang H, Tang Q, Zhang H. Randomized, double blind, placebo-controlled trial of Shuganjieyu capsule in the treatment of mild or moderate depression. Chin J New Drugs. 2009;18:413-6.
  21. Si C, Wang H, Luo M, Xie J, Chen Y, Guan H, et al. A control study on treatment of vasovagal syncope with mild-to-moderate depression and anxiety by Shugan Jieyu capsules, Flupentixol and Melitracen tablets. World Sci Technol Mod Tradit Chin Med. 2015;17(6):1230-4.
  22. Deng H, Adams CE. Traditional Chinese medicine for schizophrenia: a survey of randomized trials. Asia Pac Psychiatry. 2017;9(1):e12265.
  23. Fan M, Guo D, Tian Y, Liu Y, Zhao J. Efficacy and safety of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(8):e24856.
  24. Gong L, Yang X, Feng Y, Fei Z, Wang M, Qin B, et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke - a randomized clinical trial. Eur J Integr Med. 2020;35:101102.
  25. Yao G, Li J, Wang J, Liu S, Li X, Cao X, et al. Improved restingstate functional dynamics in post-stroke depressive patients after Shugan Jieyu capsule treatment. Front Neurosci. 2020;14:297.
  26. Li W, Liu M, Feng S, Wu B, Zhang S, Yang W, et al. Acanthopanax for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;(3):CD007032.
  27. Zhang X, Kang D, Zhang L, Peng L. Shuganjieyu capsule for major depressive disorder (MDD) in adults: a systematic review. Aging Ment Health. 2014;18(8):941-53. https://doi.org/10.1080/13607863.2014.899975
  28. Kuo J, Chen KW, Cheng IS, Tsai PH, Lu YJ, Lee NY. The effect of eight weeks of supplementation with Eleutherococcus senticosus on endurance capacity and metabolism in human. Chin J Physiol. 2010;53(2):105-11. https://doi.org/10.4077/CJP.2010.AMK018
  29. Ng QX, Venkatanarayanan N, Ho CY. Clinical use of Hypericum perforatum (St John's wort) in depression: a meta-analysis. J Affect Disord. 2017;210:211-21. https://doi.org/10.1016/j.jad.2016.12.048
  30. Rezaei A, Rezaei-Dorostkar K, Pashazadeh M, Ahmadizadeh C, Jafari B. A comparative study of sedative and anxiolytic effects of the Hypericum perforatumin and diazepam on rats. Zahedan J Res Med Sci. 2012;13(8):e93758.
  31. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.